Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

June 21, 2025

Conditions

Hidradenitis Suppurativa (HS)Hidradenitis Suppurativa (Acne Inversa)Secukinumab

Interventions

COMBINATION_PRODUCT

Surgery combined with secukinumab

Trial Locations (1)

RECRUITING

Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing

All Listed Sponsors

lead

Peking Union Medical College

OTHER